Cargando…

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy

Receptor tyrosine kinase (RTK)-related genes, including HER2, EGFR, MET, FGFR2 and KRAS, are target molecules that are clinically beneficial in gastric cancer (GC). We investigated the correlation between RTK-related genes and the curative effect of first-line S-1 plus cisplatin (SP) combination che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsusaka, Satoshi, Kobunai, Takashi, Yamamoto, Noriko, Chin, Keisho, Ogura, Mariko, Tanaka, Gotaro, Matsuoka, Kazuaki, Ishikawa, Yuichi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773703/ https://www.ncbi.nlm.nih.gov/pubmed/27014419

Ejemplares similares

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
por: Osumi, Hiroki, et al.
Publicado: (2013)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction
por: SUZUKI, SHUN-ICHI, et al.
Publicado: (2015)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
por: Kumaki, Yuichi, et al.
Publicado: (2023)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer
por: Yamada, Yasuhide, et al.
Publicado: (2019)

KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas
por: Rahman, Mohammed Tanjimur, et al.
Publicado: (2013)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
por: Sato, Yasuyoshi, et al.
Publicado: (2015)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial)
por: Ishihara, Soichiro, et al.
Publicado: (2015)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma
por: Santoni-Rugiu, Eric, et al.
Publicado: (2021)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
por: Rehkaemper, Jan, et al.
Publicado: (2020)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
por: Sun, Hongna, et al.
Publicado: (2021)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Vector Boson plus Jets background to the early MET plus Jets Search
por: D'Alfonso, Mariarosaria
Publicado: (2009)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
por: Bar, Julia K, et al.
Publicado: (2012)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

Somatic mutation detection and KRAS amplification in testicular germ cell tumors
por: Cabral, Eduardo R. M., et al.
Publicado: (2023)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ki25j2767506t2gm21e78j4rlf